S
Susumu Kobayashi
Researcher at Beth Israel Deaconess Medical Center
Publications - 648
Citations - 23408
Susumu Kobayashi is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Total synthesis & Epidermal growth factor receptor. The author has an hindex of 62, co-authored 629 publications receiving 21514 citations. Previous affiliations of Susumu Kobayashi include Chiba University & University of Tokyo.
Papers
More filters
Journal ArticleDOI
The reaction of 2-fluoropyridinium salt with nerol and geraniol. non-enzymic biogeneticlike cyclization to limonene
TL;DR: Treatment of nerol with 2-fluoropyridinium salt and tri-n-butylamine at −40°C afforded cyclic monoterpenes, mainly limonene, in high yields.
Journal Article
Copper metabolism after living donor liver transplantation for hepatic failure of Wilson's disease from a gene mutated donor
Susumu Kobayashi,Takenori Ochiai,Seiji Hori,Takao Suzuki,Takanori Shimizu,Yoshio Gunji,Hideaki Shimada,Shigenori Yamamoto,Atsushi Ogawa,Yoichi Kohno,Masahiko Sunaga,Motohide Shimazu,Koichi Tanaka +12 more
TL;DR: The gene analysis for Wilson's disease (ATP7B gene) was preoperatively carried out by the amplification refractory mutation system-PCR and homozygous and heterozygous deletion of 2871 cytosine (C) were detected in the recipient and donor, respectively, in the ATP7 B gene.
Journal ArticleDOI
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
Sho Watanabe,Yasushi Goto,Hiroyuki Yasuda,Takashi Kohno,Noriko Motoi,Yuichiro Ohe,Hiroyoshi Nishikawa,Susumu Kobayashi,Susumu Kobayashi,Kazuyoshi Kuwano,Yosuke Togashi +10 more
TL;DR: In this paper, an EGFR T790M-mutated NSCLC patient who had progressed after a third-generation EGFR-TKI, TAS-121, was subjected to a cell proliferation assay and western blotting analysis with EGFR mutations and a heat shock protein 90 (HSP90) inhibitor.
Journal ArticleDOI
Synthetic Studies on an Antitumor Antibiotic, Bleomycin. XIII. Synthesis of 2-Formylpyrimidine, a Key Intermediate for the Pyrimidine Moiety of Bleomycin
TL;DR: An efficient synthesis of the pyrimidine nucleus of bleomycin was achieved and this product was converted into ethyl 6-chloro-2-formyl-5-methylpyrimidine-4-carboxylate by treatment with POCl3.
Journal ArticleDOI
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
TL;DR: A case of a woman with advanced NSCLC treated with afatinib with sustained partial response for 20 months with manageable expected toxicities is reported, and the evolving spectrum of activity ascribed to osimertinib and newer EGFR inhibitors with a more favorable therapeutic window and intracranial penetration is summarized.